TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32505810
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral xylitol wipes (7 g xylitol)
Study: 32505810
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral hygiene regimen (SOC)
Study: 36210436
Drug: ED GOAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: ED GOAL intervention administered by trained nurses
Study: 35746524
Drug: Autogenous vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenous vaccine treatment (M. bovis, M. bovoculi, Mycoplasma bovoculi antigens)
Study: 35746524
Drug: Commercial M.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial M. bovis vaccine treatment
Study: 35746524
Drug: Sham vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham vaccine treatment (adjuvant only)
Study: 35746524
Drug: Autogenous vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenous vaccine treatment
Study: 35746524
Drug: Sham vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham vaccine treatment
Study: 34263623
Drug: Intraoperative low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative low-dose ketamine (0.2 mg/kg/h)
Study: 35862873
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg subcutaneously once every 28 days)
Study: 35862873
Drug: Tamoxifen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (40 mg orally once daily)
Study: 34822235
Drug: Spiritual intervention
Normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spiritual intervention (5 sessions before chemotherapy)
Study: 32964833
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of opioids and non-opioid CNSAM
Study: 32964833
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group (no medication use)
Study: 35460726
Drug: Vebicorvir (VBR)
Normalized name: Vebicorvir
DrugBank: Vebicorvir (DB18784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vebicorvir (VBR) 300 mg once daily + NrtI
Study: 32818353
Drug: Intracameral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral moxifloxacin (0.03 mL, 150 μg in 0.03 mL Vigamox solution)
Study: 35477618
Drug: Amphetamine Extended-Release
Normalized name: amphetamine Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine Extended-Release Tablet (AMPH ER TAB) 5 mg starting dose, titrated to 20 mg
Study: 35801274
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B (PolyB 6000 IU/kg IV, 7 doses q12h)
Study: 35801274
Drug: Polymyxin B/gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin B/gentamicin (PolyB 6000 IU/kg IV, q12h 7 doses; gentamicin 10 mg/kg IV q24h 4 doses)
Study: 35417771
Drug: Brief Intervention‐Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Intervention‐Medication Therapy Management (BI‐MTM)
Study: 32461125
Drug: Intradiscal injection
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal injection of glucocorticoids (50mg prednisolone acetate), n=24
Study: 32461125
Drug: Intradiscal injection
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal injection of lidocaine (40mg), n=26
Study: 34025075
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group (30-g or 60-g superdonor faeces)
Study: 33791095
Drug: Amoxicillin treatment
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin treatment (duration not specified)
Study: 32655260
Drug: Radical resection
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical resection combined with postoperative adjuvant chemotherapy
Study: 36137731
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy plus optional delayed ACL reconstruction (n=82)
Study: 33225615
Drug: Oxytocin (24-IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (24-IU single-dose intranasal)
Study: 33731168
Drug: Bone turnover
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone turnover marker (BTM) monitoring with alendronate, calcitriol, and calcium; medication duration was prolonged based on BTM results.
Study: 33731168
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received oral medication (alendronate, calcitriol, and calcium) for a uniform duration of 3 months.
Study: 32934804
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nefopam before surgical incision and normal saline before the end of surgery (Nefopam-Placebo)
Study: 32934804
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline before surgical incision and 30 mg of nefopam before the end of surgery (Placebo-Nefopam)
Study: 32934804
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nefopam in both timings (Nefopam-Nefopam)
Study: 33571293
Drug: Cannabis (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis (0.5 g dried cannabis flowers with 80 mg THC)
Study: 32468687
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education intervention (four nutrition classes and monthly home visits by cadres)
Study: 32468687
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard monthly health care at the health post)
Study: 36241511
Drug: Single-dose groups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose groups
Study: 34329337
Drug: HD-MAP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-MAP with 15 μg HA
Study: 32304710
Drug: Vancomycin group
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin group (pre-soaked in 5mg/ml vancomycin for 10 minutes)
Study: 34321092
Drug: Walking prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking prescription of 150 min/week during pre-surgical waiting time
Study: 36237582
Drug: Shuanghuanghua granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuanghuanghua granules (ultrafine preparation)
Study: 36237582
Drug: Shuanghuanghua granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuanghuanghua granules (extract preparation)
Study: 32395750
Drug: Modified natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified natural cycle frozen embryo transfer (modified NC-FET) with subcutaneous hCG injection to trigger ovulation
Study: 35907978
Drug: Methotrexate (concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (concomitant treatment)
Study: 33560052
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg/day (n=2903)
Study: 33560052
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg/day (n=8407)
Study: 33560052
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of telmisartan 80 mg/day and ramipril 10 mg/day (n=8334)
Study: 34809689
Drug: Fermented Rhus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented Rhus verniciflua Stokes extract (FRVE) - 129 mg fustin and 59 mg fisetin, taken as two capsules once daily for 12 weeks
Study: 34809689
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose 627.0 mg), taken as two capsules once daily for 12 weeks
Study: 37353654
Drug: Endoscopic vacuum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic vacuum therapy (EVT)
Study: 35482987
Drug: Reishimmune-S 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reishimmune-S 500 mg/day orally for 14 days
Study: 36356657
Drug: Efzofitimod 1
Normalized name: Efzofitimod
DrugBank: Efzofitimod (DB16453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efzofitimod 1 mg/kg
Study: 36356657
Drug: Efzofitimod 3
Normalized name: Efzofitimod
DrugBank: Efzofitimod (DB16453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efzofitimod 3 mg/kg
Study: 36356657
Drug: Efzofitimod 5
Normalized name: Efzofitimod
DrugBank: Efzofitimod (DB16453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efzofitimod 5 mg/kg
Study: 36356657
Drug: Efzofitimod 3
Normalized name: Efzofitimod
DrugBank: Efzofitimod (DB16453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efzofitimod 3 mg/kg and 5 mg/kg
Study: 34411627
Drug: 15 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 µg fentanyl with 10 mg hyperbaric bupivacaine
Study: 34411627
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg fentanyl with 10 mg hyperbaric bupivacaine
Study: 34411627
Drug: 7.5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 µg fentanyl with 10 mg hyperbaric bupivacaine
Study: 34411627
Drug: 0 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 µg fentanyl with 10 mg hyperbaric bupivacaine (Control Group IV)
Study: 32324238
Drug: High-dose azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose azithromycin (20 mg/kg/d)
Study: 32324238
Drug: Standard-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose azithromycin (10 mg/kg/d)
Study: 32174296
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy adapted for health anxiety (CBT-HA)
Study: 34607194
Drug: Individual Opioid
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Opioid Drug Counseling (ODC) plus buprenorphine
Study: 36228577
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment (MT)
Study: 36228577
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of multimodal treatment with aerobic training (CT)
Study: 32532299
Drug: Females with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Females with borderline high and above total cholesterol (TC ≥ 200 mg/dL)
Study: 32532299
Drug: Females with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Females with borderline high and above triglycerides (TG ≥ 150 mg/dL)
Study: 32532299
Drug: Females with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Females with borderline high and above low-density lipoprotein cholesterol (LDL-C ≥ 130 mg/dL)
Study: 32532299
Drug: Females with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Females with low high-density lipoprotein cholesterol (HDL-C < 40 mg/dL)
Study: 35491518
Drug: GIPR antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GIPR antagonist GIP(3‐30)NH2 (1,200 pmol/kg/min) with GLP‐1 infusion (0.75 pmol/kg/min)
Study: 35491518
Drug: GIPR antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GIPR antagonist GIP(3‐30)NH2 with GLP‐1 infusion
Study: 35706870
Drug: Selenium 400
Normalized name: selenium 400 MCG in 10 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium 400 μg tablets, taken three times a week after each hemodialysis session for 3 months
Study: 34011404
Drug: Protective ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective ventilation group with tidal volume (VT) of 7 ml/kg of predicted body weight (PBW) and optimal PEEP
Study: 34011404
Drug: Traditional ventilation
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional ventilation group with tidal volume (VT) of 9 ml/kg of predicted body weight (PBW)
Study: 34686780
Drug: selective internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: selective internal radiation therapy
Study: 33130569
Drug: Psychosexual education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosexual education about medical and behavioural treatment options for sexual dysfunction delivered by a haematology nurse consultant; emotionally focused therapy-based relationship education programme for couples delivered by a clinical psychologist (four sessions of 1.5 hours each).
Study: 32607598
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg riluzole
Study: 33767247
Drug: Traditional Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Medicine
Study: 32050105
Drug: Local antibiotic
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local antibiotic therapy (LAT) with metronidazole gel
Study: 37178435
Drug: Oral Semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Semaglutide
Study: 32788083
Drug: G-MEDSS (Computerised
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-MEDSS (Computerised Clinical Decision Support System)
Study: 32788083
Drug: G-MEDSS
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-MEDSS
Study: 36085067
Drug: Progressive Goal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive Goal Attainment Program (PGAP) intervention consisting of a maximum of 10 weekly individual sessions provided by a trained PGAP professional.
Study: 35612866
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg or 2.5 mg twice daily)
Study: 33386831
Drug: Myoelectrically controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myoelectrically controlled FES (MeCFES) followed by robotic therapy (MRG)
Study: 33542427
Drug: Individual dose-volume
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual dose-volume histograms (IDVHs) method for PTV DVH prediction
Study: 33542427
Drug: Distance-to-target histogram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distance-to-target histogram and conformal-plan-dose-volume histogram (DTH + CPDVH) method for OAR DVH prediction
Study: 34709859
Drug: Countermarketing and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Countermarketing and water promotion messages combined (combination group)
Study: 33737346
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment based on CTCAE grading
Study: 35088231
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus standard chemotherapy
Study: 35076138
Drug: Intraarticular injections
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injections with 20 mg gold microparticles
Study: 33369870
Drug: Intratympanic (IT)
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic (IT) dexamethasone administered once every other day for 24 days
Study: 33369870
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) dexamethasone for 12 days followed by IT dexamethasone once every other day for 12 days
Study: 33309460
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU, once daily for four weeks)
Study: 36457059
Drug: ceftolozane/tazobactam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftolozane/tazobactam (3 g [2 g ceftolozane/1 g tazobactam] every 8 h)
Study: 36457059
Drug: meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: meropenem (1 g every 8 h)
Study: 35963558
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (d-methylphenidate and guanfacine)
Study: 32965476
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (dual antiplatelet therapy) for 3 months
Study: 32965476
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus placebo (single antiplatelet therapy) for 3 months
Study: 33801537
Drug: Mobile mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile mental health apps based on cognitive behavior theory, stress theory, and ecological instant intervention theory (including breathing training, meditation, and music therapy)
Study: 32649395
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group music therapy program (3 months, twice per week, 60 minutes per session)
Study: 32649395
Drug: Daily activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activities (comparison group)
Study: 34124927
Drug: Standard clinic-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clinic-based cognitive behavioral therapy (S-CBT)
Study: 34124927
Drug: Minimal therapist
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal therapist contact cognitive behavioral therapy (MC-CBT)
Study: 36495477
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who received an opioid prescription prior to but not after OUD diagnosis
Study: 33525270
Drug: 0.3g/Kg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3g/Kg of a glucose preparation
Study: 32615837
Drug: ‘ward’ vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ‘ward’ vaginal tablet containing 200 mg of dried extract applied vaginally for 7 consecutive nights
Study: 33422263
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of renin–angiotensin system inhibitors
Study: 33422263
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of renin–angiotensin system inhibitors
Study: 33031764
Drug: Lopinavir-ritonavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir-ritonavir (400 mg and 100 mg, respectively) by mouth for 10 days or until discharge
Study: 33082286
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL 0.375% ropivacaine
Study: 33082286
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL isotonic saline (placebo)
Study: 613168068
Drug: Nicotinamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (300 mg)
Study: 613168068
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (300 mg)
Study: 34953155
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg/day for 28 days
Study: 35447502
Drug: Intravenous calcium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous calcium chloride (1 gram)
Study: 33834863
Drug: Fufang E’jiao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang E’jiao Syrup (FFEJS), 20 ml, 3 times a day for 6 weeks
Study: 33834863
Drug: Placebo, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 20 ml, 3 times a day for 6 weeks
Study: 33834863
Drug: Fufang E’jiao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang E’jiao Syrup (FFEJS)
Study: 34295831
Drug: Adjunctive probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive probiotic group (Lacticaseibacillus rhamnosus GR‐1 and Limosilactobacillus reuteri RC‐14 orally for 30 days)
Study: 34295831
Drug: Metronidazole group
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole group (metronidazole vaginal suppositories for 7 days)
Study: 34295831
Drug: Adjunctive probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive probiotic group
Study: 36944848
Drug: Lapatinib (L)
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib (L)
Study: 35238305
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg/day for 7 days)
Study: 33640423
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy (PT)
Study: 33044178
Drug: HP‐EH‐EVOO (50 mL/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP‐EH‐EVOO (50 mL/day)
Study: 33044178
Drug: MP‐EVOO (50 mL/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP‐EVOO (50 mL/day)
Study: 34042388
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of antibiotic therapy
Study: 34042388
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of antibiotic therapy
Study: 39054467
Drug: Pembrolizumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab monotherapy
Study: 35389559
Drug: Prosthesis buccal
Normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosthesis buccal emergence profile design based on the buccal mucosal W/H ratio (Test Group)
Study: 32557991
Drug: Low AM
Normalized name: Methionine,threonine,valine-free isoleucine-low amino acid mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low AM (200 mg/kg BW)
Study: 32557991
Drug: Middle AM
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle AM (400 mg/kg BW)
Study: 32557991
Drug: High AM
Normalized name: hydroxypropyl distarch phosphate, high amylose corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: High AM (800 mg/kg BW)
Study: 32557991
Drug: CON (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON (0 mg/kg BW)